Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Neurological complications were examined in a multicentre, randomized, parallel-group study of 545 patients undergoing primary liver transplantation to compare the efficacy and safety of FK 506- and cyclosporin A-based immunosuppressive regimens (CBIR). In an additional analysis, patients were divided into early and late randomized cohorts to detect the influence of protocol amendements that allowed for FK 506 dose reductions. Initial follow-up was for 6 months. Tremor, headache and insomnia were the most frequently reported adverse events involving the neurological system. Whereas these neurological symptoms were observed significantly more often in FK 506-treated patients (P < 0.05 vs. CsA for the overall population), this was no longer the case for the late FK 506 and CBIR cohorts. The risk of FK 506-treated patients developing tremor was related to the initial i.v. dose, the rate of administration of the i.v. dose and the daily dose (P < 0.01). Headache was significantly correlated with the FK 506 dose (P < 0.05), and insomnia was not related to any dosing variable. Major neurological symptoms, including psychosis, convulsion, coma, aphasia and intracranial haemorrhage, were reported with a low frequency (0.4-5.2%), and differences between both treatment groups were neither significant for the overall population nor for the early and late cohorts of FK 506 and CBIR. Data from the late cohorts showed no differences in the overall incidence of neurological adverse events between FK 506- and CBIR-treated patients.
Free University of Berlin, Universitätsklinikum Rudolf Virchow, Department of Surgery, Germany.
P
P
Neuhaus
P
P
McMaster
R
R
Calne
R
R
Pichlmayr
G
G
Otto
R
R
Williams
H
H
Bismuth
C
C
Groth
D016572:Cyclosporine / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005060:Europe; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006261:Headache / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000453:epidemiology; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced / Q000453:epidemiology; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced / Q000453:epidemiology
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D016559:Tacrolimus